# Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06161844` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06161844](<https://clinicaltrials.gov/study/NCT06161844>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06161844

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.

## Technical summary

Registry record NCT06161844. Randomized; no masking; primary purpose treatment. Start 2024-02-23 (actual); primary completion 2025-05-14 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 506 participants (enrolled count; ClinicalTrials.gov record NCT06161844, source copy `cardio:ctgov-nct06161844-2025-07-11`, retrieved 2026-10-26)
- Started: 2024-02-23 (actual) (ClinicalTrials.gov record NCT06161844, source copy `cardio:ctgov-nct06161844-2025-07-11`, retrieved 2026-10-26)
- Primary completion: 2025-05-14 (actual) (ClinicalTrials.gov record NCT06161844, source copy `cardio:ctgov-nct06161844-2025-07-11`, retrieved 2026-10-26)
- Completion: 2025-05-14 (actual) (ClinicalTrials.gov record NCT06161844, source copy `cardio:ctgov-nct06161844-2025-07-11`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06161844, source copy `cardio:ctgov-nct06161844-2025-07-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06161844-2025-07-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): semaglutide injection (HD1916)
- Intervention (Drug): Ozempic®
- Lead sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide injection for diabetes (Ozempic) (`cardio:ozempic`)
- Registry lists this organization as the lead sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (`cardio:org-cspc-zhongqi-pharmaceutical-technology-co-ltd`)

## Provenance

Content hash: b2fbcd8a5896459fee579997a533ae5135f7ffded37c4537d6498326f50bdaf5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
